망막 생물제제 시장 : 약제 클래스별, 적응증별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2023-2032년)

Retinal Biologics Market By Drug Class, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,215,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,763,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

망막 생물제제 시장은 2022년 149억 달러로 평가되며, 2023년부터 2032년까지 연평균 5.1% 성장하여 2032년에는 247억 달러에 달할 것으로 추정됩니다.

망막 질환 치료에 사용되는 생물학적 제제 중 가장 유명한 것은 라니비주맙(상품명 루센티스)으로, 노인황반변성 및 황반부종에 사용됩니다. 노인황반변성, 당뇨망막병증, 망막정맥폐쇄증 등에 사용되는 아플리버셉트(상품명 Eylea)도 자주 사용되는 생물학적 제제입니다. 베바시주맙(상품명 아바스틴)은 주로 암 치료제로 승인되었지만, 안과에서도 비슷한 적응증으로 사용되기도 합니다.

망막 생물제제 시장은 망막질환의 유병률 증가, 망막질환을 앓고 있는 노인 인구의 증가, 생명공학 및 안과 연구의 발전으로 인해 크게 성장하고 있습니다. 예를 들어,(NCBI)에 따르면 2020년 전 세계적으로 약 1억 9,600만 명이 AMD를 앓고 있으며, 전 세계 유병률은 8.69%에 달합니다. 또한 환자와 의료 전문가들 사이에서 생물학적 제제의 효과와 이점에 대한 인식이 높아지면서 시장 성장의 원동력이 되고 있습니다.

또한, 망막 생물제제 분야에서 진행 중인 연구 개발이 시장 성장에 기여하고 있습니다. 제약회사, 학계 및 연구기관은 혁신적인 치료법을 발견하고 개발하며, 치료 효과를 개선하고, 사용 가능한 망막 생물제제의 범위를 확대하기 위해 투자하고 있습니다. 예를 들어, 아테나 테라퓨틱스(Atsena Therapeutics Inc.)는 6-64세 남성 RS1 관련 X연쇄망막병증(XLRS) 환자를 대상으로 ATSN-201의 안전성과 내약성을 평가하기 위한 임상시험을 진행하고 있습니다.

또한, 유전공학, 재조합 DNA 기술, 표적 약물전달 시스템과 같은 생명공학 기술의 발전은 망막 생물학 분야에 혁명을 일으켜 시장 성장을 뒷받침하고 있습니다. 이러한 발전은 망막 질환의 근본적인 메커니즘에 특이적으로 작용하는 고도로 표적화된 효과적인 치료법을 개발할 수 있게 하여 치료 결과를 개선하고 시장 성장을 촉진하고 있습니다. 그러나 망막 치료제의 높은 비용은 망막 생물제제의 채택을 제한하고 시장 성장을 저해할 수 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
    • 다수의 조직에 의한 전략적 이니셔티브 증가
    • 망막 질환 유병률 증가
    • 노년 인구 증가
  • 성장 억제요인
    • 생물학적 제제 고가격
  • 기회
    • 신흥 시장의 성장 기회
    • 연구개발 활동 활발화
• COVID-19의 시장에 대한 영향 분석

제4장 망막 생물제제 시장 : 약제 클래스별

• 개요
• VEGF-A 길항제
• 기타

제5장 망막 생물제제 시장 : 적응증별

• 개요
• 황반변성증
• 당뇨병 망막증
• 기타

제6장 망막 생물제제 시장 : 유통 채널별

• 개요
• 병원 약국
• 드럭스토어 및 소매 약국
• 온라인 프로바이더

제7장 망막 생물제제 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카
  • 중동 및 아프리카

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10개사 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals, Inc.
• Biogen
• Novartis AG
• Coherus BioSciences, Inc.
• Bayer AG
• AbbVie Inc.
• Biocon
• Outlook Therapeutics, Inc.
• Amgen Inc.

KSM

영문 목차

영문목차

According to a new report published by Allied Market Research, titled, "Retinal Biologics Market," The retinal biologics market was valued at $14.9 billion in 2022, and is estimated to reach $24.7 billion by 2032, growing at a CAGR of 5.1% from 2023 to 2032.

One of the most well-known biologics used in the treatment of retinal conditions is Ranibizumab (brand name Lucentis), which is used for age-related macular degeneration and macular edema. Another commonly used biologic is aflibercept (brand name Eylea), which targets AMD age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Bevacizumab (brand name Avastin), although primarily approved for cancer treatment, is sometimes used off-label in ophthalmology for similar indications.

The retina biologics market has experienced significant growth owing to rise in prevalence of retinal diseases, rise in geriatric population suffering from retinal disorders diseases, and advancements in biotechnology and ophthalmic research. For instance, according to the (NCBI) in 2020, approximately 196 million people worldwide to affected by AMD, with a global prevalence of 8.69%. In addition, increase in awareness among patients and healthcare professionals about the efficacy and benefits of biologic therapies drive the market growth.

Furthermore, ongoing research and development activities in the field of retinal biologics contribute to market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available retinal biologics. For instance, Atsena Therapeutics Inc. conducting a clinical trial to evaluate the safety and tolerability of ATSN-201 in male subjects 6 to 64 years old with RS1-associated X-linked retinoschisis (XLRS).

Moreover, advances in biotechnology, such as genetic engineering, recombinant DNA technology, and targeted drug delivery systems, have revolutionized the field of retinal biologics that support the market growth. These advancements have enabled the development of highly targeted and efficacious therapies that specifically address the underlying mechanisms of retinal diseases, improving treatment outcomes and driving the market growth. However, high cost of retinal drugs may limit the adoption of retinal biologic drugs and restrain the market growth.

The retinal biologics market is segmented into drug class, indication, distribution channel, and region. On the basis of drug class, the market is bifurcated into VEGF-A antagonist and others. The VEGF-A antagonist segment is further categorized into Aflibercept, Ranibizumab, and others. On the basis of indication, the market is categorized into macular degeneration, diabetic retinopathy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. On the basis of, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Major key players that operate in the retinal biologics market are AbbVie Inc., Amgen Inc., Bayer AG, Biocon, Biogen, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. Key players have adopted product launch, product approval, and collaboration as key developmental strategies to improve the product portfolio of the retinal biologics market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the retinal biologics market analysis from 2022 to 2032 to identify the prevailing retinal biologics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the retinal biologics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global retinal biologics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

• Hospital Pharmacies
• Online Providers
• Drug Stores and Retail Pharmacies

By Drug Class

• VEGF-A Antagonist
  • Type
  • Aflibercept
  • Ranibizumab
  • Others
• Others

By Indication

• Macular Degeneration
• Diabetic Retinopathy
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Latin America
  • Middle East And Africa

Key Market Players:

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Biocon
• Biogen
• Coherus BioSciences, Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Outlook Therapeutics, Inc.
• Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in strategic Initiatives by several organizations
    • 3.4.1.2. Increase in prevalence of retinal diseases
    • 3.4.1.3. Increase in geriatric population

• 3.4.2. Restraints
  • 3.4.2.1. High cost of biologic drugs

• 3.4.3. Opportunities
  • 3.4.3.1. Growth opportunities in emerging markets
  • 3.4.3.2. Rise in R&D activities

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: RETINAL BIOLOGICS MARKET, BY DRUG CLASS

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. VEGF-A Antagonist
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. VEGF-A Antagonist Retinal Biologics Market by Type
• 4.3. Others
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: RETINAL BIOLOGICS MARKET, BY INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Macular Degeneration
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Diabetic Retinopathy
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Drug Stores and Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Providers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: RETINAL BIOLOGICS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Drug Class
  • 7.2.3. Market size and forecast, by Indication
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Drug Class
    • 7.2.5.1.3. Market size and forecast, by Indication
    • 7.2.5.1.4. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Drug Class
    • 7.2.5.2.3. Market size and forecast, by Indication
    • 7.2.5.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Drug Class
    • 7.2.5.3.3. Market size and forecast, by Indication
    • 7.2.5.3.4. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Drug Class
  • 7.3.3. Market size and forecast, by Indication
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Drug Class
    • 7.3.5.1.3. Market size and forecast, by Indication
    • 7.3.5.1.4. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Drug Class
    • 7.3.5.2.3. Market size and forecast, by Indication
    • 7.3.5.2.4. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Drug Class
    • 7.3.5.3.3. Market size and forecast, by Indication
    • 7.3.5.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Drug Class
    • 7.3.5.4.3. Market size and forecast, by Indication
    • 7.3.5.4.4. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Drug Class
    • 7.3.5.5.3. Market size and forecast, by Indication
    • 7.3.5.5.4. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Drug Class
    • 7.3.5.6.3. Market size and forecast, by Indication
    • 7.3.5.6.4. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Drug Class
  • 7.4.3. Market size and forecast, by Indication
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Drug Class
    • 7.4.5.1.3. Market size and forecast, by Indication
    • 7.4.5.1.4. Market size and forecast, by Distribution Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Drug Class
    • 7.4.5.2.3. Market size and forecast, by Indication
    • 7.4.5.2.4. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Drug Class
    • 7.4.5.3.3. Market size and forecast, by Indication
    • 7.4.5.3.4. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Drug Class
    • 7.4.5.4.3. Market size and forecast, by Indication
    • 7.4.5.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Drug Class
    • 7.4.5.5.3. Market size and forecast, by Indication
    • 7.4.5.5.4. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Drug Class
    • 7.4.5.6.3. Market size and forecast, by Indication
    • 7.4.5.6.4. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Drug Class
  • 7.5.3. Market size and forecast, by Indication
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Latin America
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Drug Class
    • 7.5.5.1.3. Market size and forecast, by Indication
    • 7.5.5.1.4. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Middle East And Africa
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Drug Class
    • 7.5.5.2.3. Market size and forecast, by Indication
    • 7.5.5.2.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. F. Hoffmann-La Roche Ltd.
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Regeneron Pharmaceuticals, Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Biogen
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Novartis AG
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Coherus BioSciences, Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Bayer AG
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. AbbVie Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Biocon
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Outlook Therapeutics, Inc.
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
• 9.10. Amgen Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료